MorphoSys, a Germany-listed biotechnology company that received venture funding, has made its first corporate venturing investment by backing Netherlands-based peer Lanthio Pharma in its series A round.
As part of the investment of undisclosed size, MorphoSys said it had preferred rights to exclusively license the Lanthio peptide technology for drug discovery.